| Literature DB >> 19379488 |
Joke Patou1, Gabriele Holtappels, Karen Affleck, Philippe Gevaert, Claudina Perez-Novo, Paul Van Cauwenberge, Claus Bachert.
Abstract
BACKGROUND: The mast cell is a crucial effector cell in allergic rhinitis and other inflammatory diseases. During the acute allergic reaction preformed mediators such as histamine, but also de novo produced mediators such as leukotrienes (LTC4/D4/E4) and prostaglandins (PGD2) are released. Mast cells represent targets for therapeutic intervention, and thus a human ex-vivo model to stimulate mast cells taken from mucosal sites would be instrumental for drug intervention studies. We have aimed to activate mast cells within ex-vivo human nasal tissue by IgE/anti-IgE specific (epsilon chain specific) stimulations and in this respect to test the usability of nasal polyps versus inferior turbinatesEntities:
Year: 2009 PMID: 19379488 PMCID: PMC2674877 DOI: 10.1186/1476-9255-6-11
Source DB: PubMed Journal: J Inflamm (Lond) ISSN: 1476-9255 Impact factor: 4.981
Patient characteristics
| N | 8 | 8 |
| Age (median, range) | 36.5 (17–47) | 38.5 (18–54) |
| Female/male | 2/6 | 4/4 |
| Asthma in history | 1/8 | 0/8 |
| Skin prick test-positive | 0/8 | 2/8 |
| Aspirin intolerance | 0/8 | 0/8 |
| Smoking | 1/8 | 1/8 |
Overview of anti-IgE and ionomycin-induced release of histamine (ng/ml), LTC4/LTD4/LTE4 (ng/ml) and PGD2 (pg/ml) after 30 minutes in the nasal polyp (n = 8) and inferior turbinate group (n = 8).
| RPMI | 24.1 (15.1–32.6) | 0.0815 (0.048–0.11) | 109 (66.5–221) |
| Versus | |||
| Anti-igE 10 μg/ml | 43.2 (28.1–55.5) | 0.469 (0.348–0.816) | 1960 (1518–4544) |
| Versus | |||
| Anti-IgE 30 μg/ml | 63.6 (44.8–75.5) | 0.675 (0.561–1.21) | 4949 (2991–6152) |
| Ionomycin 10 μM | 130 (77.5–135) | 3.40 (1.80–5.37) | 2717 (1364–4298) |
| Versus baseline | |||
| RPMI | 8.5 (5.6–12.9) | 0.036 (0.016–0.0395) | 58.6 (40.2–88.2) |
| Versus | |||
| Anti-igE 10 μg/ml | 16.2 (12.0–20.2) | 0.0655 (0.038–0.181) | 840 (492–1269) |
| Versus | |||
| Anti-IgE 30 μg/ml (n = 6) | 28.1 (21.8–31.7) | 0.0715 (0.058–0.331) | 1669 (1311–1732) |
| Ionomycin 10 μM | 27.6 (22.3–45.5) | 0.361(0.24–0.525) | 967 (548–1373) |
| Versus baseline | |||
Statistical analysis; Wilcoxon-test
Data are expressed as median +/- IQR.
Figure 1Histamine (ng/ml) (A), LTC. Comparison between nasal polyps (n = 8) and inferior turbinates (n = 8) after correction for baseline. The box-and-whisker plot represents the median, the lower to upper quartile, and the minimum to the maximum value, excluding outside and far out values, which are displayed as separate points. Statistical analyses were performed by using the Mann-Whitney U test. * p ≤ 0.05, ** p ≤ 0.001. [Black line] = inferior turbinates, [Dashed line] = nasal polyps.
Figure 2Numbers of tryptase positive cells (A) and FcεRIα positive cells (B) in the inferior turbinate group (Inf Turb) (n = 8) and the nasal polyp group (NP) (n = 8), expressed as 10 scored fields (×400). The mRNA expression of FcεRIα in the inferior turbinate group and the nasal polyp group (C). The box-and-whisker plot represents the median, the lower to upper quartile, and the minimum to the maximum value, excluding outside and far out values, which are displayed as separate points. Statistical analyses were performed by using the Mann-Whitney U test. NS = Not Significant.
Figure 3Representative staining of tryptase positive cells in inferior turbinate tissue (A) and in nasal polyp tissue (B). Representative staining of FcεRIα positive cells in inferior turbinate tissue (C) and in nasal polyp tissue (D) (× 200).